Helius Medical Technologies, Inc. to Release First Quarter of Fiscal Year 2021 Financial Results on May 17, 2021
April 07 2021 - 4:30PM
Helius Medical Technologies, Inc. (NASDAQ:HSDT) (TSX:HSM) (“Helius”
or the “Company”), a neurotech company focused on neurological
wellness, today announced that first quarter of fiscal year 2021
financial results will be released after the market closes on
Monday, May 17th.
Management will host a conference call at 5:00 p.m. Eastern Time
on May 17th to discuss the results of the quarter and fiscal year.
Those who would like to participate may dial 877-407-2988
(201-389-0923 for international callers) and provide access code
13718676. A live webcast of the call will also be provided on the
Events section of the Company's investor relations website and can
be accessed directly via the following link:
https://78449.themediaframe.com/dataconf/productusers/hls/mediaframe/44540/indexl.html.
For those unable to participate, a replay of the call will be
available for two weeks at 877-660-6853 (201-612-7415 for
international callers); access code 13718676. The webcast will be
archived on the Events section of the Company’s investor relations
website.
About Helius Medical Technologies,
Inc.
Helius Medical Technologies is a neurotech
company focused on neurological wellness. The Company’s purpose is
to develop, license and acquire unique and non-invasive platform
technologies that amplify the brain’s ability to heal itself. The
Company’s first commercial product is the Portable Neuromodulation
Stimulator (PoNS™). For more information, visit
www.heliusmedical.com.
About the PoNS Device and PoNS
Treatment
The Portable Neuromodulation Stimulator (PoNS™) is an innovative
non-surgical medical device, inclusive of a controller and
mouthpiece, which delivers mild electrical stimulation to the
surface of the tongue to provide treatment of gait deficit and is
indicated for use in the United States as a short term treatment of
gait deficit due to mild-to-moderate symptoms from multiple
sclerosis (MS) and is to be used as an adjunct to a supervised
therapeutic exercise program in patients 22 years of age and over
by prescription only. The PoNS device is authorized for sale in
Canada as a class II, non-implantable, medical device intended as a
short term treatment (14 weeks) of gait deficit due to mild and
moderate symptoms from MS, and chronic balance deficit due to
mild-to-moderate traumatic brain injury (mmTBI) and is to be used
in conjunction with physical therapy. The PoNS device is an
investigational medical device in the European Union (“EU”) and
Australia (“AUS”). It is currently under premarket review by the
AUS Therapeutic Goods Administration.
Investor Relations Contact:
Westwicke Partners on behalf of Helius Medical Technologies,
Inc.
Jack Powell, Vice President
investorrelations@heliusmedical.com
Helius Medical Technolog... (NASDAQ:HSDT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Helius Medical Technolog... (NASDAQ:HSDT)
Historical Stock Chart
From Apr 2023 to Apr 2024